Texas Ibogaine Research: What It Does and Does Not Tell Us About Ketamine

Texas interest in ibogaine research has generated questions about other mental health treatments, including ketamine. Research funding can support scientific investigation, but it does not establish that a drug works, that it is appropriate for you, or that a different medication has the same effects.

What Texas has announced

Texas enacted an ibogaine research law in 2025. In a March 31, 2026 statement, state leaders described plans for a state research program after proposals had not met the requirements for the earlier funding approach. These are dated policy developments, not a statement that a trial is currently enrolling or that ibogaine has received FDA approval.

If you are considering a clinical study, confirm its current status directly with the research team. Ask about eligibility, oversight, possible harms, costs, and the consent process. Do not treat a funding announcement or personal account as evidence of an established treatment.

Why ibogaine findings cannot validate ketamine

Ibogaine and ketamine are different substances. Research on one cannot prove the other’s benefit for PTSD, addiction, depression, or brain injury. Even within ketamine research, the formulation, route, dose, diagnosis, and monitoring setting affect how findings should be interpreted.

Compounded ketamine is not FDA-approved. FDA has not reviewed compounded medications for safety, effectiveness, or quality before marketing. Ketamine injection is approved for anesthesia, not psychiatric disorders. Compounded ketamine nasal spray is different from Spravato, the FDA-approved esketamine product used in certified healthcare settings.

PTSD care needs its own evidence

The current VA/DoD PTSD guideline suggests against ketamine for PTSD and recommends specific trauma-focused psychotherapies. A separate assessment of co-occurring depression may lead to different treatment discussions. Improvement in depression should not be presented as proof that PTSD itself has been successfully treated.

Questions beyond the headlines

• Is this a funding decision, a registered trial, a published result, or an approved indication?
• Were outcomes compared with an appropriate control group?
• What is known about longer-term harms and follow-up?
• Does this evidence apply to the exact product and setting being offered?

Patients in Texas do not need to wait for research headlines to ask about established care. A clinician can review current symptoms, prior treatment, and practical barriers to accessing the options already recommended for the condition.

Risks and the treatment setting

Ketamine can cause sedation, dissociation, impaired thinking or coordination, increased blood pressure, and slowed breathing. Other concerns include abuse or misuse, worsening psychiatric symptoms, and urinary or bladder problems. A prescription or lower dose does not eliminate these risks.

At home, a healthcare professional is not onsite to monitor you or respond immediately to an adverse reaction. Virtual follow-up does not provide the same monitoring as an onsite team. Discuss whether the setting is appropriate, your medication interactions, and an emergency plan before treatment.

Discuss your questions with a clinician

Bliss Mist Rx LLC provides telehealth services and does not compound or manufacture medications. If treatment is prescribed, an independent, appropriately licensed compounding pharmacy dispenses the medication. A consultation does not guarantee a prescription; applicable prescribing and compounding requirements must be met.

Book a Free Virtual Appointment or Follow-Up to review your questions, alternatives, and next steps. This article provides general education and does not replace individualized medical advice.

Further reading: Texas: 2025 research law; Texas: March 2026 program statement; VA: PTSD medication guidance; FDA: compounded-drug risks.